Skip to main content
NovartisPatent grant

Novartis was granted a patent for compounds targeting coronavirus diseases.

Source: Autobound Signal API · 77 signals tracked for Novartis · updated

Get Novartis' live signals in Claude or ChatGPT, or by API

AskWhat changed at Novartis this week? Use Autobound signals for novartis.com.

What happened

In October 2026 Novartis patented drug candidates and formulations for treating, managing, or preventing coronavirus-related diseases in clinical and patient-care settings.

Source

patents.google.comOct 27, 2026

US patent US12774275

Compounds and compositions for the treatment of coronaviral related diseases

Abstract

Provided herein are compounds and compositions for treating, managing or preventing coronaviral related diseases. In particular, provided herein are compounds which are inhibitors of SARS-CoV-2 main protease (Mpro), pharmaceutical compositions comprising such compounds, method for synthesizing such compounds and methods of using such compounds and compositions for the treatment, management or prevention of coronaviral related diseases.

patents.google.com/patent/US12774275Read the full source

Extracted by Autobound

From the Signal API record
Signal
Patent grant

What this signalsA new patent often shows where a company is putting its R&D budget.

Grant date
Oct 27, 2026
Inventors
4
Patent number
US12774275
Assignee
Novartis ag

The full record

From the Signal API record

People

  • Denghui BaoInventor
  • Fengfeng GuoInventor
  • Matthew James HesseInventor
  • Viktor HornakInventor
  • Sajan JosephInventor
  • Thomas Martin Kirrane, Jr.Inventor

Details

Primary CPC class
C07D 401/14
USPTO assignee
Novartis ag
What the invention does
A group of medicines designed to block SARS-CoV-2’s main protease, an enzyme the virus needs to reproduce.

Topics and mentions

Tags

  • Intellectual Property
  • Research & Development
  • Pharmaceuticals
  • Medical Research

Technologies named

  • antiviral compounds
  • SARS-CoV-2 protease inhibitors
  • pharmaceutical formulations

Extraction

Detected
Oct 30, 2026
signal_type
patents-company
signal_subtype
patentGrant

Use this data

Get every patent signal for Novartis and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Novartis this week?”

  2. Send it to your own tools

    The Signal API returns patent signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full patents-company record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/e1000844-204c-5539-9652-960aee5bfbad returns this record as JSON. POST /v1/companies/enrich returns every signal for novartis.com.

{
  "signal_id": "e1000844-204c-5539-9652-960aee5bfbad",
  "signal_type": "patents-company",
  "signal_subtype": "patentGrant",
  "detected_at": "2026-10-30T00:08:50+00:00",
  "company": {
    "name": "Novartis",
    "domain": "novartis.com"
  },
  "data": {
    "cpc": [
      {
        "code": "C07D 401/14"
      },
      {
        "code": "A61K 31/4725"
      },
      {
        "code": "A61K 31/501"
      },
      {
        "code": "A61K 31/506"
      },
      {
        "code": "A61P 31/14"
      }
    ],
    "tags": [
      "Intellectual Property",
      "Research & Development",
      "Pharmaceuticals",
      "Medical Research"
    ],
    "detail": "In October 2026 Novartis patented drug candidates and formulations for treating, managing, or preventing coronavirus-related diseases in clinical and patient-care settings.",
    "summary": "Novartis was granted a patent for compounds targeting coronavirus diseases.",
    "event_at": "2026-10-27",
    "inventors": [
      {
        "name": "Denghui Bao",
        "status": "unresolved",
        "is_primary": true
      },
      {
        "name": "Fengfeng Guo",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/fengfeng-guo-05286159"
      },
      {
        "name": "Matthew James Hesse",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/matthew-hesse-7929bb170"
      },
      {
        "name": "Viktor Hornak",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "Sajan Joseph",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "Thomas Martin Kirrane, Jr.",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "Haiyao Lin",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "Bo Liu",
        "status": "unresolved",
        "is_primary": false
      }
    ],
    "event_kind": "grant_date",
    "grant_date": "2026-10-27",
    "source_url": "https://patents.google.com/patent/US12774275",
    "cpc_primary": {
      "code": "C07D 401/14"
    },
    "patent_title": "Compounds and compositions for the treatment of coronaviral related diseases",
    "patent_number": "US12774275",
    "uspto_assignee": "NOVARTIS AG",
    "patent_abstract": "Provided herein are compounds and compositions for treating, managing or preventing coronaviral related diseases. In particular, provided herein are compounds which are inhibitors of SARS-CoV-2 main protease (Mpro), pharmaceutical compositions comprising such compounds, method for synthesizing such compounds and methods of using such compounds and compositions for the treatment, management or prevention of coronaviral related diseases.",
    "precision_class": "structural",
    "invention_explanation": "A group of medicines designed to block SARS-CoV-2’s main protease, an enzyme the virus needs to reproduce.",
    "technologies_mentioned": [
      "antiviral compounds",
      "SARS-CoV-2 protease inhibitors",
      "pharmaceutical formulations"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.